Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.

NCT05321862 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped MIDAS inclusions terminated before first inclusion in PENTI-MIDAS

Conditions

Multiple Myeloma

Interventions

DRUG: [68Ga]Ga-PentixaFor

Sponsor

Nantes University Hospital